Brief: Immix Biopharma Doses Additional Patients In Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical Trial
13/01/2023 14:24
Jan 13 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA DOSES ADDITIONAL PATIENTS IN ONGOING PHASE
1B/2A
IMX-110 MONOTHERAPY CLINICAL TRIAL
* IMMIX BIOPHARMA INC - IN JANUARY 2023, 17(TH) NEW PATIENT
WAS
DOSED WITH IMX-110 TO DATE
* IMMIX BIOPHARMA INC - CLINICAL DATA EXPECTED TO BE
RELEASED ON A
ROLLING BASIS BEGINNING IN Q1 2023
* IMMIX BIOPHARMA INC - TO SHARE CLINICAL DATA FROM IMX110
MONOTHERAPY & IMX110 COMBINATION TRIAL WITH BEIGENE/NOVARTIS
ANTI-PD1 TISLELIZUMAB IN Q1 2023
Source text for Eikon: ID:nGNX8MZ0pG
Further company coverage: IMMX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary